Total Health
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Total Health
Jun 25, 2024, 14:59 |
Societies
Sarah Louden: The 2024 summer ASCO Direct review tour officially kicked off
Sarah Louden, Founder and CEO of Total Health, shared on LinkedIn: "The 2024 summer ASCO…
May 29, 2024, 14:50 |
Insight
Sarah Louden: I feel blessed to have an incredible team of a beautiful cancer education company
Sarah Louden, Founder and CEO at Total Health, recently shared on LinkedIn: “As most of…
May 18, 2024, 06:11 |
Blog
Pedro Barata: Excited to join as a speaker at the upcoming 2024 ASCO Direct Hawaii Conference!
Pedro Barata, Associate Professor at University Hospitals Seidman Cancer Center, shared on LinkedIn: "Excited to…
Mar 1, 2024, 03:42 |
Blog
Sarah Louden: The University of Kansas Cancer Center Breast Cancer Year in Review!
Sarah Louden, Founder and CEO at Total Health, recently shared on LinkedIn: "Another incredible conference! The…
Sep 23, 2023, 10:56 |
Blog
Marianne Sarcich: Excited to join Total Health as a speaker at the upcoming 2023 Evolution Conference.
Marianne Sarcich, Breast Cancer Survivor/National Advocate, made the following post on LinkedIn: "Excited to join…
Sep 11, 2023, 17:23 |
Blog
Sarah Louden: The power of women! What an incredible weekend at the Best of Lung with Total Health | Oncology.
Quoting Sarah Louden, Founder and CEO of Total Health, on LinkedIn: ''The power of women!…
Aug 19, 2023, 19:52 |
Blog
Sarah Louden: Our explosive growth is fueled by the company's mission to arm cancer care teams, as well as people living with cancer, with the latest research and strategies.
All:
7
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube